Laura Deming is currently a full-time partner at The Longevity Fund, an early stage venture capital fund backing companies which target the aging process to treat disease, with investments in gene editing, small molecule therapeutics, and novel methods to treat disease.
When she was 8, Laura Deming realized that we were all going to die of a disease called aging. Ever since, her driving passion has been to slow aging and eliminate age-related disease. She started working in a biogerontology lab when she was 12, and matriculated at MIT when she was 14. At 17, she was one of the youngest 20under20 fellows awarded $100,000 by Peter Thiel to pursue her venture full time.